Anzeige
Meldung des Tages: Großes Umsatzwachstum: Warum ein Hidden Champion im Drohnenmarkt gerade Aufmerksamkeit bekommt

Pharming Group News

Aktie
WKN:  A1H65A ISIN:  NL0010391025 US-Symbol:  PHGUF Branche:  Biotechnologie Land:  Niederlande
1,389 €
+0,004 €
+0,29%
10.03.26
Depot/Watchlist
Marktkapitalisierung *
987,30 Mio. €
Streubesitz
76,27%
KGV
-
Index-Zuordnung
-

Pharming Group News

26.02.26 - GlobeNewswire
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
Leiden, the Netherlands, February 26, 2026:  Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its ...
17.02.26 - GlobeNewswire
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Leiden, the  Netherlands, February 17, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in ...
03.02.26 - GlobeNewswire
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
Highlights advancing clinical-​stage pipeline, including two major value-​creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-​driven ...
01.02.26 - GlobeNewswire
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a ...
21.01.26 - EQS
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
Original-​Research: Pharming Group NV - from First Berlin Equity Research GmbH 21.01.2026 / 16:13 CET/CEST Dissemination of a Research, transmitted by EQS News - a service ...
08.01.26 - GlobeNewswire
Pharming Group reports preliminary 2025 revenues and announces Investor Day
Leiden, The Netherlands, January 8, 2026:  Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, ...
08.12.25 - GlobeNewswire
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
Leiden, the  Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the ...
06.11.25 - GlobeNewswire
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, ...
30.10.25 - GlobeNewswire
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Leiden, the  Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will ...
23.10.25 - GlobeNewswire
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Leiden, the Netherlands, October 23, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) ...
01.10.25 - GlobeNewswire
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency ...
03.09.25 - GlobeNewswire
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Leiden, the  Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will ...
20.08.25 - EQS
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
Original-​Research: Pharming Group NV - from First Berlin Equity Research GmbH 20.08.2025 / 16:37 CET/CEST Dissemination of a Research, transmitted by EQS News - a service ...
04.08.25 - GlobeNewswire
Pharming Group to participate in August investor conference
Leiden, the  Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate ...
31.07.25 - GlobeNewswire
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth ...
17.07.25 - GlobeNewswire
Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
Leiden, the Netherlands, July 17, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) ...
28.05.25 - GlobeNewswire
Pharming Group to participate in June investor conferences
Leiden, the  Netherlands, May 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in ...
08.05.25 - GlobeNewswire
Pharming Group reports first quarter 2025 financial results and provides business update
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to ...
24.04.25 - GlobeNewswire
Pharming Group to report first quarter 2025 financial results on May 8
Leiden, the Netherlands, April 24, 2025:  Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first ...
23.04.25 - GlobeNewswire
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years ...

Newssuche

Videos

newspaper
10.03.26 +38,58%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »